Yacha Sutton - BIO VIEW Director

  Director
Director. We currently do not have informatin regarding Yacha Sutton. This executive tanure with BIO VIEW is not currenlty determined.
Age: 64  Director Since 2004      
972 73 227 1025  http://www.bioview.com

BIO VIEW Management Efficiency

BIO VIEW has return on total asset (ROA) of (3.69) % which means that it has lost $3.69 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (6.08) %, meaning that it generated substantial loss on money invested by shareholders. BIO VIEW management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.57 M in total debt with debt to equity ratio (D/E) of 11.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BIO VIEW has a current ratio of 2.1, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BIO VIEW until it has trouble settling it off, either with new capital or with free cash flow. So, BIO VIEW's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BIO VIEW sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BIO VIEW to invest in growth at high rates of return. When we think about BIO VIEW's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Arnon ZuaretzREKAH PHARMA IND
2016
Sagi SchliesserMAGIC SOFTWARE ENT
2015
Ilan HoreshREKAH PHARMA IND
2007
Naamit SalomonMAGIC SOFTWARE ENT
2003
Orly ZilbermanREKAH PHARMA IND
2015
Liat BinyaminiE SCHNAPP WORKS
2011
Bracha PolskyLitvakISROTEL LTD
2016
Simon LouisISROTEL LTD
2005
Yigal FatranMEDIVIE THERP M
2014
Moshe MagidISROTEL LTD
1992
Jacob GoldmanISROTEL LTD
2007
Amiram BoehmREKAH PHARMA IND
2015
Avi PrestmanE SCHNAPP WORKS
2009
Elan PennMAGIC SOFTWARE ENT
2005
Varda TrioksE SCHNAPP WORKS
2007
Georgette ElgrablyREKAH PHARMA IND
2015
Ifat ZakE SCHNAPP WORKS
2016
David KirkISROTEL LTD
2016
Itzhak ArbelE SCHNAPP WORKS
2011
Revital DganiISROTEL LTD
2007
Ishay DavidiREKAH PHARMA IND
2015
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel. BIO VIEW (BIOV) is traded on Tel Aviv Stock Exchange in Israel and employs 12 people.

BIO VIEW Leadership Team

Elected by the shareholders, the BIO VIEW's board of directors comprises two types of representatives: BIO VIEW inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIO VIEW. The board's role is to monitor BIO VIEW's management team and ensure that shareholders' interests are well served. BIO VIEW's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIO VIEW's outside directors are responsible for providing unbiased perspectives on the board's policies.
Elad Kfir, Vice President of Marketing
Eliane Markowitz, External Director
Yuval Harari, Co-CEO, Director
Emmanuel Gill, Chairman of the Board
David Kutas, CEO of BioView Inc - USA and President of BioView Inc - USA
Yacha Sutton, Director
Marina Wolfson, CFO
Alan Schwebel, CEO and Pres
Jackie RosenblumGoren, External Director
Inbal Hillel, Vice President - Operations
Lior Shav, Director
Eliyahu AyalonLanciano, External Director
Warren Esanu, Director

BIO VIEW Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIO VIEW a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BIO VIEW in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BIO VIEW's short interest history, or implied volatility extrapolated from BIO VIEW options trading.

Pair Trading with BIO VIEW

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BIO VIEW position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BIO VIEW will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Schlumberger could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Schlumberger when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Schlumberger - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Schlumberger NV to buy it.
The correlation of Schlumberger is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Schlumberger moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Schlumberger NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Schlumberger can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Tools for BIO VIEW Stock

When running BIO VIEW price analysis, check to measure BIO VIEW's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIO VIEW is operating at the current time. Most of BIO VIEW's value examination focuses on studying past and present price action to predict the probability of BIO VIEW's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move BIO VIEW's price. Additionally, you may evaluate how the addition of BIO VIEW to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go